Although targeting FGF2 signalling as a cancer therapy has been lagging behind that of other receptor tyrosine kinases, including epidermal growth factor (EGF) signalling, clinical reagents that specifically target the FGFs or FGF receptors are being developed and included in clinical trials (Turner and Grose 2010). This evidence concerns the gene FGF2 and cancer.